Advancing evidence. Influencing policy. Improving patient outcomes.
In 2025, Columbia Data Analytics strengthened its position as a leader in real-world evidence and health economics research, delivering high-impact publications and presenting across the world’s most influential scientific forums. Our work this year spanned mental health, women’s health, obesity, chronic disease and health policy, helping translate real-world data into meaningful insights for providers, payers and policymakers.
Peer-Reviewed Publications
Mental Health & Medicaid Policy
- Open access to antipsychotics in Medicaid and its impact on utilization and cost among patients with serious mental illness J Health Econ Outcomes Res
- Impact of copay accumulators and maximizers on treatment patterns and adherence in major depressive and bipolar disorders J Mark Access Health Policy
- The effect on healthcare resource utilization and costs among patients with serious mental illness J Health Econ Outcomes Res
- Impact of Medicaid IMD exception on serious mental illness outcomes. Am J Manag Care. 2025; in press.
- Effects of the Medicaid IMD exclusion and Medicaid reimbursement policies on serious mental illness outcomes Am J Manag Care. 2025; in press.
Prevalence and risk factors among patients with alcohol use disorder during COVID-19: National survey on drug use and health analysis Med Res Arch
Women’s & Reproductive Health
- The Effect of Dobbs v. Jackson Women’s Health Organization on clinical diagnosis of postpartum depression J Health Econ Outcomes Res
Metabolic & Chronic Disease
Real-world external control arm evaluating semaglutide and chronic kidney disease risk Expert Opin Pharmacother
Tirzepatide and semaglutide for the treatment of obstructive sleep apnea and obesity: A retrospective analysis Med Res Arch
Rare Disease
Rare-event analysis of IVIG therapy for bullous pemphigoid using DoD data BMC Res Methodol
Scientific Presentations
CDA contributed to more than 35 posters at major national and international conferences.
Academy of Managed Care Pharmacy (AMCP) Annual Meeting
Houston, TX: March 31 – April 3, 2025
- Real-world treatment patterns, healthcare resource utilization and costs for Medicaid patients with a postpartum depression diagnosis
- Open access to antipsychotics in state Medicaid programs: The effect on healthcare resource utilization and costs among patients with serious mental illness
ISPOR Annual Meeting
Montreal, QC: May 13-16, 2025
- Comparison of suicidal ideation or personal history of self harm among patients with use of Rexulti and all antipsychotics
- Postpartum depression: Assessing the aftermath of Dobbs v. Jackson in trigger and non-trigger states
- Shades of blue: Investigating racial, socioeconomic, and family dynamics in depression among teen girls
- Socioeconomic status and anti-obesity medications: Impact on cardiovascular risk in Medicare patients with obesity
- Machine learning algorithms for identifying undiagnosed nonalcoholic steatohepatitis: A Veterans Affairs health system study
- External control arm with real world data to assess the effect of semaglutide on chronic kidney disease risk among patients with type 2 diabetes
ACOG Annual Clinical & Scientific Meeting
Minneapolis, MN: May 16-18, 2025
- Evaluating the relationship between Medicaid postpartum depression (PPD) screening and coverage policies on PPD diagnosis incidence in the US
- Real-world clinical outcomes among patients receiving the long-acting injectable antipsychotic TV-46000 vs second-generation oral antipsychotics
- Treatment patterns and healthcare resource utilization among patients receiving the long-acting injectable antipsychotic TV-46000 vs second-generation oral antipsychotics
National Network of Depression Centers 17th Annual Conference
Cincinnati, OH: Sept 10-11, 2025
- Evaluating the association between Medicaid postpartum depression (PPD) screening and coverage policies with PPD diagnosis incidence in the US
AMCP Nexus
Baltimore, MD: Oct 27-30, 2025
- Socioeconomic vulnerabilities and postpartum depression: Assessing the aftermath of Dobbs v Jackson in trigger and non-trigger states
- The impact of copay accumulators and maximizers on treatment patterns and costs among patients with major depressive and bipolar disorders treated with branded mental health treatments
- Improved outcomes in patients with multiple sclerosis initiating cladribine tablets compared with those denied health insurance coverage in the United States
ISPOR Europe
Nov 9-12, 2025: Glasgow, Scotland, UK
- Comparative prevalence of suicidal ideation and self-harm history: Rexulti vs other oral atypical antipsychotics
- Does the abortion pill harm women? Serious adverse events following mifepristone abortion in US commercial and Medicaid populations
- Effect of the Inflation Reduction Act on drug innovation
- Overall treatment landscape of mucosal melanoma
- Socioeconomic disparities in access to treatment for major depressive disorder: The role of accumulator and maximizer insurance plans
- Socioeconomic disparities in postpartum depression following abortion restrictions: A difference-in-differences analysis of Medicaid data post-Dobb
Looking Ahead
Our 2025 body of work reflects CDA’s commitment to:
Methodological rigor
Policy-relevant real-world evidence
Actionable insights for life sciences decision-makers
Contact us for feasibility and our data source expertise
Beyond Fit-for-purpose, we make data work for your purpose.
We look forward to continuing to support evidence generation that improves access, informs policy and advances patient outcomes.
